The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

期刊论文
出版模式：

开放获取
发表日期：

2024年5月17日

查看全文

Yutaka Shimazu,
Junya Kanda,
Yoshiyuki Onda,
Shin-ichi Fuchida,
Kensuke Ohta,
Yuji Shimura,
Satoru Kosugi,
Ryosuke Yamamura,
Mitsuhiro Matsuda,
Hitoshi Hanamoto,
Yoko Adachi,
Naoyuki Anzai,
Masaaki Hotta,
Kentaro Fukushima,
Hideo Yagi,
Satoshi Yoshihara,
Yasuhiro Tanaka,
Teruhito Takakuwa,
Hirokazu Tanaka,
Hirohiko Shibayama,
Nobuhiko Uoshima,
Naoki Hosen,
Tomoki Ito,
Chihiro Shimazaki,
Itaru Matsumura,
Junya Kuroda,
Akifumi Takaori-Kondo,
Masayuki Hino

摘要

Background

Isatuximab, an anti-CD38 antibody, has been widely used in treatments for patients with relapsed/refractory multiple myeloma (MM). Despite its high efficacy, not all patients achieve a lasting therapeutic response with isatuximab.

Objective

We tried to identify biomarkers to predict the effectiveness of isatuximab by focusing on the host's immune status before treatment.

Methods

We retrospectively analyzed the cases of 134 relapsed/refractory MM patients in the Kansai Myeloma Forum database who had received only a first isatuximab treatment.

Results

Among the 134 patients, an isatuximab, pomalidomide and dexamethasone (Isa-PD) regimen, isatuximab, carfilzomib and dexamethasone (Isa-KD) regimen and isatuximab and/or dexamethasone (Isa-D) regimen were used in 112, 15 and 7 patients, respectively. The median age at treatment, number of prior treatment regimens, and progression-free survival (PFS) were 71, 6, and 6.54 months, respectively. Multivariate analysis showed that the PFS under the Isa-PD regimen was longer in patients with higher lymphocyte/monocyte ratio (LMR ≥ 4), fewer prior treatment regimens (< 6), and no use of prior daratumumab treatment. The OS under the Isa-PD regimen was longer in patients with higher white blood cell counts (WBC counts ≥ 3000/μL) and higher LMR. The PFS under the Isa-D regimen was longer in patients with fewer prior treatment regimens in univariate analysis, but no parameters were correlated with PFS/OS under the Isa-KD regimen.

Conclusion

We found that the patients with higher LMR (≥ 4) could obtain longer PFS and OS under the Isa-PD regimen. Other cohort studies of isatuximab treatment might be necessary to substantiate our results.